About BMS Clinical Trials
What we offer
BMS Clinical Trials is a website to help potential patients who are considering taking part in a clinical trial. The trials can be downloaded to have a discussion with your family and doctor. If you’re ready to take the next step in your journey you can answer a few questions to see if you might be eligible, choose a study you match to and a trial site that is located conveniently for you. A study team member at the trial site you have chosen will contact you to begin the process. It is the trial site physician’s final decision about whether you are eligible to participate.
NEX-T Study
BMS is conducting a clinical trial to evaluate the tolerability, preliminary efficacy, and pharmacokinetics of a study drug in adult participants, ages 18-75 years old, with severe refractory Systemic Lupus Erythematosus (SLE). This is a phase 1 study with 11 study sites in the United States. The study treatment period will last about 28 days, with follow up approximately every 28 days for 6 months, then quarterly follow up for about 2 years.
Click here to learn more about the NEXT-T Study
POETYK SLE-1 and SLE-2 Study
BMS is conducting a clinical trial to evaluate the effectiveness, safety, and tolerability of a study drug in adult participants, ages 18-75 years old, with active Systemic Lupus Erythematosus (SLE). This is a phase 3 study currently being conducted in 16 countries including the United States. The study will last over 1 year, about 60 weeks.
POETYK SLE-1 (IM011-246) and POETYK SLE-2 (IM011-247) are two identical SLE clinical trials evaluating the safety and effectiveness of an investigational study medication in adults with active systemic lupus erythematosus (SLE).
Participants will be randomly assigned to receive either the study medication or a placebo. All participants will continue to take their usual lupus treatment while on study medication. The study medication (or placebo) is one tablet taken by mouth twice daily.
If you are eligible, you would only participate in one of these two studies. Remember: Taking part in a clinical trial is voluntary, and if you enroll, you can choose to leave the study at any time.
Who may participate in these studies?
You may qualify for one of these research studies, if the following eligibility criteria are met:
- 18 to 75 years of age
- Diagnosed with SLE
- Currently have a rash and/or arthritis due to lupus
- Positive antibodies (ANA, or anti-dsDNA or anti-Smith) based on lab screening
- On treatment for lupus with an anti-malarial, an immunosuppressant medication, or one of each
- No other autoimmune disease except type 1 diabetes mellitus, thyroid autoimmune disease, celiac disease, or secondary Sjogren’s syndrome
Additional eligibility criteria will be explained to you by the study doctor.
Other Available Lupus Clinical Trials from BMS
WELCOME
Thank you for visiting this website to learn more about OPUS (Oral S1P1 Receptor ModUlation in SLE) – a clinical study testing an investigational drug, cenerimod, for the treatment of Systemic Lupus Erythematosus (SLE*).
The decision to participate in a clinical study is a very personal one. On this website, you will find detailed information about what the OPUS study involves, which you can read at your own pace. If you think that joining the OPUS study might be the right choice for you, speak to your doctor to understand the complete details of the program and how to register to potentially join the study.
*SLE is the full name for the syndrome known as Lupus. If you are not sure about the condition, discuss with your doctor for better understanding.
Visit the official Cenerimod OPUS Clinical Trials website